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ABSTRACT 
 
A common pathological hallmark of most neurodegenerative disorders is the presence 
of protein aggregates in the brain. Understanding the regulation of aggregate formation is 
thus important for elucidating disease pathogenic mechanisms and finding effective 
preventive avenues and cures. Amyotrophic Lateral Sclerosis (ALS), also known as Lou 
Gehrig’s disease, is a selective neurodegenerative disorder predominantly affecting motor 
neurons.   The majority of ALS cases are sporadic, however, mutations in superoxide 
dismutase 1 (SOD1) are responsible for about 20% of familial ALS (fALS). Mutated SOD1 
proteins are prone to misfold and form protein aggregates, thus representing a good candidate 
for studying aggregate formation. 
The long-term goal of this project is to identify regulators of aggregate formation by 
mutant SOD1 and other ALS-associated disease proteins. The specific aim of this thesis 
project is to assess the possibility of using the well-established Drosophila model system to 
study aggregation by human SOD1 (hSOD1) mutants. To this end, using wild type and the 
three mutant hSOD1 (A4V, G85R and G93A) most commonly found among fALS, I have 
generated 16 different SOD1 constructs containing either eGFP or mCherry in-frame 
fluorescent reporters, established and tested both cell- and animal-based Drosophila hSOD1 
models. The experimental strategy allows for clear visualization of ectopic hSOD1 
expression as well as versatile co-expression schemes to fully investigate protein aggregation 
specifically by mutant hSOD1.   
I have performed pilot cell-transfection experiments and verified induced expression 
of hSOD1 proteins. Using several tissue- or cell type-specific Gal4 lines, I have confirmed 
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the proper expression of hSOD1 from established transgenic fly lines. Interestingly, in both 
Drosophila S2 cells and different fly tissues including the eye and motor neurons, robust 
aggregate formation by either wild type or mutant hSOD1 proteins was not observed.  These 
preliminary observations suggest that Drosophila might not be a good experimental organism 
to study aggregation and toxicity of mutant hSOD1 protein. Nevertheless this preliminary 
conclusion implies the potential existence of a potent protective mechanism against mutant 
hSOD1 aggregation and toxicity in Drosophila.  
Thus, results from my SOD1-ALS project in Drosophila will help future studies on 
how to best employ this classic model organism to study ALS and other human brain 
degenerative diseases. 
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CHAPTER ONE 
Introduction 
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Amyotrophic Lateral Sclerosis 
 
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that 
predominantly and selectively affects upper and lower motor neurons in the brain and spinal 
cord.  ALS, in the US is more commonly known as Lou Gerig’s disease and is diagnosed at a 
rate of about 5,600 new cases a year, affecting a total of 30,000 Americans at any given time 
("ALS association," 2013).  The pathology of this disorder is characterized by a deterioration 
of the neuromuscular junction (NMJ), caused by the retraction and progressive degeneration 
of motor neuron axons (healthy NMJ is seen in figure 1). This results in sensory loss, muscle 
weakness, muscle atrophy and eventually paralysis.  In human patients ALS symptoms onset 
is varied but usually begins with sporadic weakness or stiffness and then progresses to 
systemic weakness and loss of function.  Paralysis and a complete loss of mobility occur at 
advanced stages of disease and eventually dysfunction of respiratory motor neurons occurs.  
Death is usually the result of paralyzed respiratory muscles and occurs within 1 to 5 years of 
diagnosis, but has been document to take up to 20 years after diagnosis (Bruijn, Miller, & 
Cleveland, 2004).  Although, in later stages total loss of motor function is very common, 
control of eye muscles and movement as well as bladder function often remains unaffected.     
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Figure 1. Healthy motor neuron and neuromuscular junction.  
This is a diagram of a typical motor neuron and its connection to the neuromuscular junction 
(NMJ).   
Image (A) shows a basic understanding of vesicle, protein and mitochondria trafficking to 
and from axon terminals.  
Image (B) depicts action potential generated at the soma and propagated down the neuron 
with sodium entry towards the NMJ.  That action potential provides the necessary cytosolic 
increase in calcium required to facilitate neurotransmitter release  
Figure 1. Healthy motor neuron and neuromuscular junction. 
A) 
B) 
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Genetic basis of ALS 
 
Most cases of ALS are sporadic with no known genetic component, 5 to 10% of ALS 
is familial.  Among the familial Amyotrophic Lateral Sclerosis (fALS) cases, around 20 – 
40% are caused by one of over 150 identified mutations in the superoxide dismutase 1 
(SOD1) gene and about 50% of fALS are due to a hexanucleotide repeat expansion mutation 
in an intron of the C9orf72 gene.  Interestingly around 44 mutations in the TDP-43 gene, 
which codes for an RNA binding protein, are responsible for about 5% of all sporadic and 
familial ALS (Da Cruz & Cleveland, 2011; Kwiatkowski et al., 2009; Mackenzie, 
Rademakers, & Neumann, 2010).  However, a total of 46 identified mutations so far in the 
Fused in Sarcoma or Translocated in liposarcoma (FUS/TLS) gene, another RNA binding 
protein, is seen in around 4% of familial ALS, but rarely seen in sporadic ALS (Da Cruz & 
Cleveland, 2011; Vance et al., 2009).   
Superoxide dismutase (SOD) 
 
Among the many ALS-associated genes, SOD1 is the first identified and by far most 
extensively studied.  In mammalians, there are three different superoxide dismutase enzymes 
and they are found at three different cellular locations. ALS-associated superoxide dismutase 
1 (SOD1) is a cytosolic enzyme that causes the dismutation of the highly reactive   
  anion 
known as superoxide, to H2O2, which then can be further reduced to water (H2O) and 
molecular oxygen (O2).  Superoxide dismutase 2 (SOD2) resides in the mitochondria while 
superoxide dismutase 3 (SOD3) is an extracellular protein.  Notably, mutations in SOD2 
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have also been found to cause motor neuron disease and to exacerbate ALS caused by SOD1 
mutations (van Zundert, Izaurieta, Fritz, & Alvarez, 2012).  
ALS-associated mutation in SOD1 
 
SOD1 itself encodes a small protein of 153 amino acids (a.a.) long and is fully 
functional as a homodimer.  Remarkably, over 150 mutations distributed throughout this 
small protein have been identified in ALS patients.  Among the most well characterized 
mutations in SOD1, an alanine (A) to valine (V) change at position 4 (A4V) is the most 
common mutation in fALS patients, and a glycine (G) to alanine (A) change at position 93 
(G93A) was employed to create the first established mouse ALS model (van Zundert et al., 
2012).  Notably, SOD1 proteins harboring either of these two mutations are still 
enzymatically active as superoxide dismutase, although they become physically unstable and 
prone to aggregation. Another commonly modeled SOD1 mutation is a glycine (G) to 
arginine (R) change at position 85, referred to as G85R, which is commonly referred to as 
enzymatically inactive, although detailed studies suggest it retains a very low level of 
activity.  However, SOD1 protein with this G85R mutation is more unstable as compared to 
other SOD1 mutants and aggressively forms aggregates (Bruijn et al., 1997; Wang et al., 
2009). 
Thus, far only one mutation in SOD1, D90A, has been seen to cause fALS in a 
recessive manner, while all other mutations cause fALS in a dominant manner. The recessive 
mutation of SOD1 is predominantly seen in a small subset of the Scandinavian population 
and appears to be recessive only in that population (Robberecht et al., 1996). 
SOD1-based ALS models in mice 
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 Modeling of SOD1 mutations related to ALS in mice has been successful in that it 
produces animals with consistent phenotypes that accurately reflect the disease course in 
humans.  One exception is that in ALS mouse models, the onset of weakness and paralysis 
presents very consistently in the hind limbs, in contrast to the sporadic or non-uniform onset 
of the symptoms in human patients.  Also, among the reported ALS mouse models, different 
disease relevant mutations of SOD1 cause consistent and nearly uniform symptoms. With 
variation in disease course mostly limited to the age of onset and length of disease course, 
making findings in one model relevant to other models. Two exceptions are notable, first 
G127X mutation in SOD1 induces symptoms at low expression levels, although still 
accumulates in CNS tissue and results in both protoaggregates and aggregates.  It is in 
contrast with other more common ALS models that mostly rely on overexpression of mutated 
SOD1 (Jonsson et al., 2004).  Second, A4V mutation in SOD1 appears to require either a 
high level of protein expression, a common feature of mutant SOD1models, or co-expression 
with wild type SOD1(Deng et al., 2006). 
Mutant SOD1 induces a gained of toxicity 
 
The pathogenic mechanisms underlying ALS are still far from clear (see Chapter 2 
below). The reason SOD1 mutations are so tightly linked to ALS is also not yet known.  
However, SOD1-associated ALS in general is believed to be the result of a gain of toxicity in 
mutant SOD1, because many mutant forms of the protein remain catalytically active.  In 
addition, for those mutations that do not retain the endogenous SOD1 function, they do not 
correlate with correspondingly altered severity of the symptoms or an earlier onset of the 
disease (Boillee, Vande Velde, & Cleveland, 2006; Bruijn et al., 2004; Ince et al., 2011; 
Pasinelli & Brown, 2006).  Moreover, mice with SOD1 knock out do not develop motor 
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neuron degeneration symptoms, but instead have been found to have increased incidence of 
tumor formation, although this does not impact survival or accelerate aging biomarkers 
(Boillee, Vande Velde, et al., 2006; Muller, Lustgarten, Jang, Richardson, & Van Remmen, 
2007; Reaume et al., 1996). 
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CHAPTER TWO 
Pathogenic Mechanisms of ALS: A Literature Review 
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Protein aggregates: a common pathological feature of many neurodegenerative diseases 
 
Amyotrophic Lateral Sclerosis, Parkinson’s, Alzheimer’s, transmissible spongiform 
encephalopathy’s and Huntington’s are neurodegenerative diseases that affect different areas 
of the brain and involve different gene mutations.  Nevertheless, they all involve the gradual 
loss of neurons.  At the pathological level, almost all brain disease share a common feature: 
the formation and presence of aberrant protein deposits (aggregates).   
It is generally believed that protein aggregates are derived from accumulation of mis-
folded proteins.  The protein aggregates are composed primarily of unique proteins in 
different diseases.   For example, in Parkinson ’s disease (PD), the Lewy body is mainly 
composed of PD-associated α-Synuclein protein; In Huntington’s disease (HD), the 
inclusions contain the cleaved and mis-folded disease gene product Huntingtin; In 
Alzheimer’s disease (AD), the extracellular plaques are predominantly consisted of secreted 
Aβ peptides derived from processed AD gene product APP, while the intracellular tangles are 
from the hyper-phosphorylated Tau protein. Similarly, the protein products of the ALS-
associated genes such as mutant SOD1, TDP43 or FUS have also been found in neuronal 
aggregates from ALS patients (Bruijn et al., 2004). The close link between protein aggregates 
and brain degenerative diseases has promoted speculations of a causative relationship 
between abnormal protein deposition and neurodegenration. 
 Protein aggregation is a simple term for a highly complex process that involves a 
dynamic equilibrium between soluble monomers or oligomers of accumulated protein and 
various states of higher order insoluble structures termed aggregates.  The path from 
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accumulated protein to aggregate is dependent on cellular environment, interaction with other 
proteins and concentration of the accumulated protein (Aguzzi & O'Connor, 2010).   In the 
case of SOD1 associated fALS, there is an aberrant accumulation of mutant SOD1 protein 
accompanied by a lack of degradation by the ubiquitin mediated degradation pathway, 
resulting in aggregated inclusions consisting of mis-folded mutant SOD1 protein, as depicted 
in figure 4 below (Bruijn et al., 2004). It has also been suggested the protein half-life plays a 
role in SOD1 mutations ability to aggregate aggressively and might be an indicator of 
aggregate formation (Wang et al., 2003).  
However, there is a growing body of empirical evidence to suggest the actual 
formation of protein fibrils may be either neuroprotective or the end stage by-product of the 
real culprit.  That is, earlier stage prefibrillar oligomers or protofibrils have been implicated 
as the true source of toxic element responsible for neuronal cell death (Caughey & Lansbury, 
2003).  It has been suggested that accumulated mutant proteins could overload protease 
machinery, overtax heat shock proteins and damage mitochondria, increasing the risk of cell 
death due to oxidative stress and thus inducing apoptosis.  As an example of the complexity 
of the field, one study that illustrates the toxicity of pre-aggregate oligomers of mutant SOD1 
in ALS focused on the G127X mutation that will produce a truncated SOD1 protein. This 
study found that mutant G127X SOD1 will cause ALS, even with fewer aggregates and at 
lower expression levels than other SOD1 mutants, which suggests that an overtaxing or 
sequestering of chaperones does not occur in some cases (Jonsson et al., 2004).  Further, it 
has been shown that mis-folded mutant G127X SOD1 can exist at higher steady state levels 
between synthesis, mis-folded accumulation and degradation/aggregation in the central 
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nervous system, than elsewhere in an organism, suggesting a possible reason for CNS 
susceptibility to disease (Jonsson et al., 2004).     
The above findings regarding the G127X mutation of SOD1 underscore the 
possibility that oligomers and protofibrils may be more damaging than fully formed 
aggregates. Sorting out the true cause of neurodegeneration and understanding the cellular 
regulation process of forming aggregates will be critical to developing effective treatments 
for ALS. 
Astrocytes and Glia Cells: A brief introduction 
 
Although ALS is a motor neuron disease, increasing evidence suggest an essential 
role of neuronal supporting cells especially astrocytes and glia in the disease pathogenesis 
(Nagai et al., 2007; Perea & Araque, 2005; Rao & Weiss, 2004; Wallis, Zagami, Beart, & 
O'Shea, 2012).  Glia cells fall into two basic classifications based on their location they are 
either central glia or peripheral glia.  Central glia cell types include microglia, astrocytes, 
oligodendrocytes and ependymal cells.  Schwann cells are the only type of peripheral glia 
cells; they sheath axons and cover the cell bodies of neurons (Hammond, 2008).   
Astrocytes were first believed to only be “brain stuffing” or the glue and structure, 
which provided the physical support that facilitated the organization and connections of 
neurons and to supply nutrients to neurons via liaison with and maintenance of the blood 
brain barrier (Volterra & Meldolesi, 2005).  In the late 1980s it was discovered that 
astrocytes expressed voltage gated ion channels as well as receptors for neurotransmitters, 
suggesting they played a more sophisticated role in neural tissue than previously thought 
(Volterra & Meldolesi, 2005).  
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Prevalent dogma in the neuroscience field also held that astrocytes and glia cells 
could not participate in neuronal communication because they do not generate an action 
potential when excited.  Now it is known that astrocytes and glia are excitable without the 
ability to generate an action potential, which has given new depth to the complexity of 
communication occurring in the brain (Bezzi & Volterra, 2001).  Even without generating an 
action potential astrocytes and glia are capable of excitation, which results in the release of 
neurotransmitters to neighboring cells (Zonta, Angulo, et al., 2003; Zonta, Sebelin, et al., 
2003).  Further astrocytes and glia are active communicators in neuronal circuits with 
exocytosis of synaptic-like microvesicles containing neurotransmitters, such as glutamate, 
has been documented and diagramed in figure 2 (Matsui & Jahr, 2003, 2004).  The excitation 
of both glia and astrocytes can be quantified as a transient increases and subsequent decrease 
in calcium concentration (Zonta, Sebelin, et al., 2003).  The two predominant forms of 
excitation have been documented and are either the result of chemical signals released by 
local neuronal circuits or can occur spontaneously in the absence of a canonical signal or 
trigger (Volterra & Meldolesi, 2005). Importantly, when astrocytes or glia display excitation 
through an increase in cytosolic calcium concentration they can directly excite adjacent 
neurons (Fellin et al., 2004).   This knowledge lead to the discovery that astrocytes play an 
important role in many processes, including the formation and function of synapses as well 
as adult neurogenesis and in maintaining the vascular tone of the brain (Bushong, Marton, & 
Ellisman, 2004; Bushong, Martone, Jones, & Ellisman, 2002; Derouiche & Frotscher, 2001).  
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Figure 2 Astrocytes play an active role in synaptic cleft traffic and neuron response. 
Glutamate released from the pre-synaptic neuron travels across the cleft to activate the 
AMPA and NMDA receptors on the post synaptic cleft.   
If glutamate is not cleared from the synaptic cleft by the EAAT2 glutamate reuptake 
transporter in the neighboring astrocytes, it will remain in the cleft and bind more receptors 
that are present or inserted into the membrane.  Potentially inducing excessive signaling and 
excitoxicity. 
 
  
Figure 2. Astrocytes play an active role in synaptic cleft traffic and neuron response. 
14 
 
Astrocytes have been shown to be involved in almost every functional aspect of the 
central nervous system from neurogenesis and synaptogenesis, to acting as local integration 
units and liaisons between synaptic and non-synaptic communication (Denise et al., 2004; 
Mauch et al., 2001; Sanai et al., 2004; Seri, Garcia-Verdugo, McEwen, & Alvarez-Buylla, 
2001). The role of glia cells in neuronal signaling was also underestimated, now it is known 
that glia cells can regulate synaptic function and structure (Mauch et al., 2001; Ullian, 
Sapperstein, Christopherson, & Barres, 2001).   
There are two documented examples where glia-cell signaling, to the neuron, directly 
regulates synaptic function and structure. The first includes Bergmann glial cells, where a 
calcium concentration increases resulting from glutamate activated AMPA receptors, 
maintains the extensive network of synapses that innervate Purkinje cells(Volterra & 
Meldolesi, 2005).  The absence of this glia signal alters the hyperinnervation and synaptic 
current of the postsynaptic targets. (Iino et al., 2001)  The second example is the binding of 
ephrin A3, which is released from the surface of astrocytic processes, to its receptor EphA4, 
which is expressed on dendritic spine membranes. This event initiates intracellular signals 
that control the shape, size and number of dendritic spines. Without this signal spines will 
grow too long and become very disorganized (Murai, Nguyen, Irie, Yamaguchi, & Pasquale, 
2003). This information sets new precedents for understanding how information flow and 
trafficking in neuronal networks is established by excitation of both neurons and glia and 
astrocytes. It also serves to bring attention to the ability of astrocytes/glia to dynamically and 
extensively respond to the state of neurons and synaptic communication.  
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Astrocytes and Glia Cells: Role in ALS 
 
Astrocytes inclusions, as they relate to ALS were described by Beckman et al. in a 
study that attempts to establish a timeline for motor neuron degeneration. The inclusion  
resembled the lewy bodies found in Parkinson’s and were found to be the first abnormalities 
in G85R mutant hSOD1 expressing mice(Beckman, Estevez, & Crow, 2001).  This occurred 
in the mutant mice at 8 to 10 months of age and was seen before inclusions were detected in 
motor neurons.  Astrocyte localization was confirmed with immunoreactivity to antibodies 
specific to glial fibrillary acid protein (GFAP), which is not expressed in neurons. A two fold 
increase in SOD1 concentration was seen in the spinal cords of dissected mice along with a 
10 fold increase in SOD1-G85R containing astrocyte inclusions at end stage and this was 
accompanied by a marked increase in astrocytosis.  
Aggregates of SOD1 were then seen only in a few neurons before onset of symptoms, 
but were diffuse and small, though they were reactive to SOD1 and ubiquitin antibodies.  At 
later stages of disease large round and irregular shaped SOD1 containing inclusions were 
observed that were immunoreactive to SOD1 antibodies at their core and periphery.  These 
inclusions were reactive to ubiquitin, however only at the periphery.   In the final stage of 
disease spinal cord extracted showed a 60% loss of motor axons and a 10 fold increase in 
mutant SOD1 astrocyte inclusions over motor neuron inclusions.  Indicating that the astroglia 
are a major focus of damage for ALS associated SOD1 mutation G85R (Beckman et al., 
2001). 
Microglia cells are myeloid-lineage immune cells of the central nervous system.  
They and astrocytes are the primary inflammatory response mediators.  Microglia has been 
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shown in some cases to cross the blood brain barrier (BBB) and or the blood spinal cord 
barrier to communicate and interact directly with the immune system (Boillee, Yamanaka, et 
al., 2006; Skaper & Facci, 2012; Weydt & Moller, 2005). Mast cells are bone marrow 
derived innate immune system cells that are capable of crossing the blood brain barrier and 
blood spinal cord barrier in the absence of inflammation.  They are capable of producing 
many inflammatory and neurotrophic mediators, key to ALS are tumor necrosis factor-α 
(TNFα) and nerve growth factor, to which glia cells may respond (Skaper & Facci, 2012).   
Neuron death can be caused by microglia activation and secretion of toxic factors 
such as TNFα and nitric oxide (NO) can be released from astrocytes expressing mutated 
SOD1 proteins, which encourages pro-apoptotic pathways in motor neurons (Volterra & 
Meldolesi, 2005).  Release of toxic factors from astrocytes and glia ultimately kill motor 
neurons through the activation of BAX mediated cell death agents (Nagai et al., 2007).   
Importantly, it has been shown that among the many non-neuronal cells astrocytes are the 
only cell type that are capable of releasing such toxic factors and motor neurons are the only 
type of neuronal cells that are killed by these toxins (Nagai et al., 2007). 
Motor neuron death also involves excitotoxicity which may be mediated by 
astrocytes, as they are the major mediators of neuronal support.  Astrocytes are responsible 
for the regulation of ion concentrations in the extracellular space, as well as modulation and 
clearance of neurotransmitters, such as glutamate,  from the synaptic cleft (Benediktsson, 
Schachtele, Green, & Dailey, 2005; Hirrlinger, Hulsmann, & Kirchhoff, 2004; Volterra & 
Meldolesi, 2005).  
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In ALS there are reports of the focal loss of the EAAT2 transporter (normal function 
seen in figure 2) in astrocytes, which is the dominant transporter responsible for glutamate 
reuptake.  Glutamate is the major excitatory neurotransmitter (Parpura et al., 1994) and with 
the reuptake of glutamate inhibited, glutamate is left in the synaptic cleft free to bind to any 
available receptors.  This will result in the activation of a cation channels that will depolarize 
the neuron and can ultimately result in repetitive neuronal excitability, calcium entry and 
eventually excitotoxicity through repetition.   In addition to glutamate excitotoxicity as a 
result of the loss of EAAT2 transporter in astrocytes, the release of D-serine from glia, which 
causes chronic activation of NMDAR, has also been linked to mutant SOD1 and ALS 
(Sasabe et al., 2007).    
Mitochondria dysfunction in ALS 
 
Mitochondria are classically described as the power house of the cell and as such it is 
the primary source of ATP production.  To achieve this vital role, it employs a very complex 
system that utilizes three partitioned domains which are the matrix, inner membrane space 
and the outer membrane. Using a set of intramembranous protein complexes in located in 
their inner membrane, mitochondria are able to establish and maintain and electron transport 
chain (ETC) for the purpose of stripping electrons and collecting protons (H
+
 atoms) from 
molecules as seem in figure 3.     
Notably, SOD1 is the major cytosolic protein present to prevent oxidative damage 
and reduce superoxide leakage form mitochondria.  It has also been shown that SOD1 is 
present in the mitochondria, primarily in the inter membrane space but also in the matrix and 
on the cytosolic face of the outer membrane. (Carri & Cozzolino, 2011).  The presence of 
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SOD1 is thought to provide protection to mitochondrial proteins from oxidation thus 
preserving mitochondrial homeostasis (Aquilano, Vigilanza, Rotilio, & Ciriolo, 2006; 
Kloppel, Michels, Zimmer, Herrmann, & Riemer, 2010; O'Brien, Dirmeier, Engle, & Poyton, 
2004).  Accordingly, mutations in SOD1 and its abnormal aggregation have been suspected 
to disrupt this important cellular protective mechanism and contribute to the disease 
pathogenesis. 
Axonal transport of mitochondria has been shown to be dysfunctional in ALS and 
could indeed be related to the problems caused by mutant SOD1 presence in mitochondria 
(Carri & Cozzolino, 2011; De Vos, Grierson, Ackerley, & Miller, 2008; Magrane & 
Manfredi, 2009).  Mutant SOD1 has been shown to localize to the inner membrane space and 
matrix of the mitochondria with the aid of its copper chaperone (CCS), which binds to 
Mia40.  They then enter the mitochondria (depicted in figure 3) through the Erv1/Mia40 
oxidative folding mechanism of import (Carri & Cozzolino, 2011).  Once inside the 
mitochondria, mutant SOD1 accumulates in and forms oligomers  (Deng et al., 2006; Ferri et 
al., 2006) (Furukawa, Fu, Deng, Siddique, & O'Halloran, 2006).   
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Figure 3 Wild type function of ETC and localization of SOD1 in mitochondria. 
Protons are stored and allowed to build up in the inter membrane space while at the same 
time electrons are sent into the matrix where they contribute to a buildup of negative charge 
gradient thus establishing a negative potential in the matrix.  This negative membrane 
potential then attracts protons as well as positively charged amino acids that are part of the 
localization signaling sequence for mitochondrial proteins. The movement of protons from 
the inner membrane space to the matrix is what drives the protein complex that produces 
ATP.  As a consequence of this process a deadly byproduct called superoxide (  
   is 
produced, establishing mitochondria as the major producer of toxic reactive oxygen species. 
(Carri & Cozzolino, 2011). 
 
Further, there are reports that mitochondrial association of PTEN-induced kinase 
(PINK1), a PD-linked serine/therine kinase, together with the activation of microtubule-
associated protein 1 light chain 3 (LC3) occurring together are signs of mitochondrial 
autophagy activation and have been shown to be induced by overexpression of mutant SOD1 
(Carri & Cozzolino, 2011; Ferri et al., 2006; Morimoto et al., 2010; Morimoto et al., 2007; 
Figure 3 ETC and localization of SOD1 in mitochondria 
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Pizzasegola et al., 2009).  PINK1 itself has been implicated in mitophagy a cellular process 
of removing dysfunctional mitochondria. (Deas, Wood, & Plun-Favreau, 2011) This process 
may be activated as a result of disruption of mutant SOD1 to the electron transport chain 
(ETC) (Cozzolino et al., 2009) and can lead to mislocalization of mitochondria from the 
neural muscular junction as seen in figure 4 (Nguyen, Garcia-Chacon, Barrett, Barrett, & 
David, 2009).  Indeed, mitochondrial mislocalization in the axon has been seen in ALS and is 
suggested to be a cause of axonal degeneration (Han et al., 2012; Tsuda et al., 2008).   
Additionally, mutant SOD1 can aggregate in the matrix or inter membrane space and 
measures to remove or decrease aggregated mutant SOD1 in mitochondria has been shown to 
be effective at protecting the cell from mutant SOD1 induced toxicity (Carri & Cozzolino, 
2011). 
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Figure 4 Aggregates of SOD1 can inhibit axonal travel and mitochondria localization.  
Image (A) depicts aggregates of mutant SOD1 may inhibit vesicle travel and mitochondria 
localization to axon terminal.  Thus contributing to axonal detachment and retraction from 
the neuromuscular junction (NMJ)>\. 
Image (B) shows an action potential which may be ineffective because of axon retraction 
from the neuromuscular junction, exacerbating the degeneration process.    
 
  
A) 
B) 
Figure 4. Neuromuscular junction deterioration  
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Aberrant Calcium Signaling in ALS 
 
One study has shown that human mutant SOD1-G93A in SH-SY5Y cells showed a 
decreased ability to clear calcium from the cytosol to intracellular storage sites, such as the 
mitochondria and endoplasmic reticulum, or to the extracellular space.  It has been postulated 
that this inability to clear calcium from the cytosol could account for the lack of calcium 
oscillation seen in these mutant SOD1 transfected cells (Jaiswal et al., 2009).  This leads to a 
calcium buildup as a result of a storage and handling deficit, which is seen as an increase in 
cytosolic calcium concentration a hallmark of excitotoxicity and deadly to the neuron.  
It has been shown with thapsigargin treatment, which induces endoplasmic reticulum 
(ER) stress, of SH-SY5Y cells transfected with G93A mutation of hSOD1 that selective 
release of calcium from the (ER) only slightly increases cytosolic calcium concentration over 
the similarly tested wild-type hSOD1 expressing cells.  This indicates that dysfunction of 
stores of calcium in the ER only slightly contributes to motor neuron dysfunction and 
confirms the mitochondria as major players with regard to calcium accumulation and 
dysfunction (Jaiswal et al., 2009). When mitochondrial ability to store calcium becomes 
dysfunctional as seen in G93A mutant SOD1 transfected cells, neurons are then subject to 
cytosolic calcium accumulation.  This then puts greater stress on the neuron and leaves it 
susceptible to calcium mediated cell death pathways resulting in neruodegeneration (Jaiswal 
et al., 2009).   
Cytosolic increases in calcium concentration, which are seen in ALS, may be the 
result of oxidative stress to mitochondria (see below) and can lead to an increase in the 
production of nitric oxide and peroxynitrite both of which could be deadly to the cell (Rao & 
Weiss, 2004; Raoul et al., 2002).   
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Oxidative Stress 
 
As noted, SOD1 is the major cytosolic protein to prevent oxidative damage and 
reduce superoxide leakage form mitochondria.  It has been proposed that mutant SOD1 could 
reverse its protective catalytic activity, instead of scavenging and dismutation of superoxide 
(  
 ) to hydrogen peroxide (H2O2) and molecular oxygen (O2), it might be able revert to 
produce toxic superoxide (Beckman et al., 2001; S. I. Liochev & Fridovich, 2000; Stefan I. 
Liochev & Fridovich, 2003).  This could be the result of mutations that leave SOD1 defective 
in binding co-factor Zinc (Stefan I. Liochev & Fridovich, 2003).  In such a state SOD1 could 
actually take electrons from other cellular antioxidants and then donate them to molecular 
oxygen, thus producing superoxide, making SOD1 the source of the oxidative 
stress(Beckman et al., 2001).  The end result is postulated to be the production of 
peroxynitrite (ONOO) from superoxide and nitric oxide (Beckman & Koppenol, 1996). This 
would cause the production of tyrosine nitration by reaction with peroxynitrite. It is 
suggested that the critical protein affected by nitro-tyrosine residues is microtublues, thus 
interfering with their ability to polymerize, which in turn could inhibit proper subcellular 
trafficking and localization of mitochondria and neurotransmitter vesicle travel. (Beckman et 
al., 2001)  However, the clinical and experimental evidence does not support that hypothesis 
(Boillee, Vande Velde, et al., 2006; Bruijn et al., 2004; Stefan I. Liochev & Fridovich, 2003).   
Similar hypothesis regarding aberrant neuronal chemistry caused by the inability of 
mutant SOD1 to complex with Cu and Zn leaving excess cytosolic Cu and Zn ions to run 
amuck in the neurons have also not been supported by experimental and clinical data(Boillee, 
Vande Velde, et al., 2006).  Additionally, mice transfected with SOD1
quad
 mutants, which 
have completely null copper-binding sites, did not show signs of  any of the above mentioned 
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aberrant chemistry that would result in toxic superoxide or nitration species nor is disease 
course altered (Wang et al., 2003).  
ALS as a result of mutant SOD1 is not related to superoxide buildup and thus not a 
consequence of oxidative damage or stress cause by superoxide.  Individual mutations have 
been documented to be throughout the SOD1 gene and yet all cause the same neuronal 
degeneration with minimal differentiation.  Sporadic and familial ALS, along with other 
neurodegenerative diseases have signs consistent with a deficit in protein homeostasis, such 
as aggregation and mislocalization of mutated and wild type RNA regulatory proteins, like 
TDP-43.  Thus, questions regarding aberrant protein accumulation and aggregation must be 
solved in order to comprehensively address neurodegeneration.  Elucidating genes which are 
involved in the regulation of the aggregate formation process could contribute to a more 
complete understanding of neurodegeneration as a whole.  
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CHAPTER THREE 
The Goal of the Project and the Research Design 
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The goal of this project   
 
The goal of this project is to test the feasibility of using Drosophila model system to 
study the regulation of aggregates formed by the human SOD1 (hSOD1) protein.  Abnormal 
protein aggregation is a prominent pathological hallmark of ALS. Their formation, by the 
ALS-associated disease proteins such as mutant SOD1, TDP43, FUS1, has been linked to the 
dysfunction and degeneration of motor neurons during disease pathogenesis.  In particular, 
mutations in the small SOD1 gene have been established to be the cause of 20% of familial 
ALS. The long-term goal of the project is to systematically identify and analyze the 
regulators of aggregates formation by the mutated human SOD1 and other ALS-associated 
protein.  This will enable further dissection of the molecular networks that regulate 
intracellular protein mis-folding and clearance in general, as well as provide potential targets 
for therapeutic interventions against this fatal disease.   
Drosophila, an excellent model organism to study human diseases  
 
Drosophila, one of the best-studied genetic organisms, has emerged as an excellent 
model system to study human brain degenerative diseases.  Although a simple model 
organism, the fruit fly offers several important advantages.  For example, as a relatively 
simple invertebrate, it is small in size, easy to maintain and care for, and can be raised in 
large quantities at low cost.  Second, it has high fecundity and short generation time, which is 
usually not longer than 13 days from egg to reproductive-competent mature adult.  These 
features make Drosophila an ideal system to be subjected to large-scale and detailed genetic 
analysis.  In fact, over the last one hundred years, the fruit fly has been one of the most 
extensively characterized and genetically manipulated multi-cellular organisms. In that time 
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a large arsenal of sophisticated experimental tools have been developed, such as the easily-
applied transgenic techniques and targeted mutagenesis.  Utilized by many and important to 
this study is the UAS-Gal4 binary expression system for targeted overexpression or 
knockdown of a target gene.  Further, clonal mosaic systems for analyzing lethal mutations 
and differentiating cell-autonomous effect.  Along with the recently developed genome-wide 
dsRNA libraries and RNAi transgenic lines for convenient knock-down of every single gene 
in the fly genome in both cultured cells and the whole animals. Moreover, Drosophila has a 
well-documented developmental process as well as extensively studied and highly-conserved 
signaling pathways.  Notably, many important signaling pathways such as Wingless/Wnt, 
Notch, Hedgehog and Toll/innate immunity, were first discovered and elucidated in the fruit 
flies and still bear their original colorful names from this simple species.  Furthermore, the 
fly genome also contains homologs of many human neurodegenerative disease genes, such as 
PD genes Parkin and Pink1, HD gene Huntingtin, AD gene App and Tau and ALS gene 
SOD1 and TDP43. Importantly to this study, the fruit fly also has a relatively simple yet 
conserved nervous system that bears many similarities with that in humans.  These include, 
but are not limited to, diverse neuronal cell types such as sensory and motor neurons, the 
existence of glia cells, as well as the similar neuronal transmitters such as histamine, 
dopamine and glutamate signaling. Over the last decade, many human brain degenerative 
diseases including AD, PD and HD have been successfully modeled in the fruit fly (Bilen & 
Bonini, 2005; Marsh & Thompson, 2006).  Finally, of particular relevance to this study, 
Drosophila and human copper chaperons have been shown to be highly conserved and 
functionally interchangeable (Hua, Georgiev, Schaffner, & Steiger, 2010).  Thus, wild type 
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and mutant hSOD1 expressed in Drosophila is likely to complex with copper as it would in 
mammalians.  
Experimental Design 
Cell line- and whole animal-based ALS/SOD1 models in Drosophila   
 
To study the regulation of the aggregate formation process by mutant SOD1, we have 
decided to develop both cell line- and whole animal-based human SOD1 models in 
Drosophila. The cell line-based model allows quick analysis of hSOD1 protein expression 
and aggregation potential in vitro.  Further, the cell-based model can very easily scaled up 
such as to 384-well plate format that can be used for to high-throughput cell-based screens 
such as RNAi or bioactive compounds. The whole-animal based hSOD1 model enables us to 
analyze the in vivo effect of SOD1 in their ability to develop aggregates and induce toxicity 
in different tissues and cell types such as neuron verse glia.  If both models are successful, 
we can further establish stable cell line models that express mutant human SOD1.  Such a 
cell model is amenable to high-throughput screens such as genome-wide RNAi to quickly 
investigate every gene in the fly genome for their role in regulating mutant hSOD1 
aggregation and toxicity.  Extending this study to a screen for chemical compounds that 
could directly yield potential drug candidates would be quick and simple.  Subsequently, the 
whole-animal models can facilitate in vivo validation of any identified hits from the cell-
based screens. 
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Selection of hSOD1 mutations for the study 
   
For mutant hSOD1, we will focus on the three most-characterized ALS mutations: 
A4V, G85R and G93A.  Human SOD1 mutation A4V it the most prominent mutation of 
fALS associated SOD1, and has been shown to be particularly unstable and aggressive at 
forming aggregates ("ALS association," 2013; Boillee, Vande Velde, et al., 2006).  However, 
it remains catalytically active as does the well characterized G93A mutation which was used 
to establish the first hSOD1 associated ALS mouse model (Bruijn et al., 2004; Spalloni et al., 
2004). Furthermore like mutation A4V of SOD1 the G85R is also aggressive at forming 
aggregates, but is catalytically dysfunctional (Boillee, Vande Velde, et al., 2006; Watson, 
Lagow, Xu, Zhang, & Bonini, 2008). The mutations focused on for this study provide a good 
representative sample of the over 150 ALS associated hSOD1 mutations.  As the control, we 
will include the wild type human SOD1 (WT-hSOD1) in all the studies to eliminate 
background effect and false positives.  
Tagging with fluorescent reporters for convenient monitoring of SOD1 protein 
expression and aggregate formation 
 
To facilitate convenient visualization of gene expression and subsequent aggregate 
formation, both wild type (WT) and mutant hSOD1 will be fused to either eGFP or mCherry 
fluorescent proteins with a short flexible linker mainly composed of small amino acid glycine 
and serine (GS). The use of the two different fluorescent reporters allows easy distinction of 
mutant hSOD1 and control WT- hSOD1 proteins co-expressed in the same cell.  For 
example, in the cell-based model, plasmids containing wild-type hSOD1 fused to mCherry 
reporter will be co-transfected with mutant hSOD1 with eGFP reporter.  With this co-
transfection scheme, the presence of red-colored WT-hSOD1 will serve as an internal control 
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for the protein expression level of transfected DNA, which is a critical factor in protein 
aggregation.  More importantly, it also allows clear distinction of whether the effect on 
aggregate formation from a study is specific for mutant hSOD1, which will be the targets of 
interest for follow up study.  Or are the observed effects on aggregate formation non-specific 
and affect both mutant and WT-hSOD1.  Such an observation would likely mean we have a 
false positive due to background effect and should be disregarded.  
Cell-based model  
 
We have selected the pMK33 vector as cloning template mainly for the following 
reasons.  First, pMK33 contains a copper-inducible metallothionein promoter, which allows 
for temporal control of SOD1 expression by the addition or removal of copper from the 
medium.  This is preferred over constitutive expression such as by actin promoter which 
might not be feasible for potentially toxic proteins such as SOD1.  In addition, insoluble 
aggregates may be impervious to regulation, thus for an accurate assessment of a gene’s 
ability to regulate aggregate formation, it must be knocked down significantly before 
aggregates form. Thus, in a RNAi or compound screen, before inducing hSOD1 expression, 
we are able to first incubate the cells in the reagents such as dsRNA.  This can be done for a 
significant amount of time so as to efficiently knockdown the expression level of the target 
gene.  Moreover, it is important to consider that eGFP can take hours to fold completely and 
fluoresce(Chudakov, Matz, Lukyanov, & Lukyanov, 2010). Lastly, this vector contains a 
hygromycin resistance gene, which will allow for convenient establishment of stably 
transfected cell-line through hygromycin selection.   
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Animal-based model  
  
For the animal-based model, we will use the pUAST transgenic vector as cloning 
template, which can be conveniently combined with the Gal4 system to achieve targeted 
expression of studied genes in almost any temporal- and spatially-controlled manner in the 
transgenic flies diagramed in figure 5. 
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Figure 5 The GAL 4-UAS binary expression system in Drosophila is originally derived 
from S. cerevisiae.  
In the yeast, in the presence of galactose as a primary source of food, yeast will 
express a family of genes under the upstream activating (UAS) response element, which is 
recognized and activated by the GAL4 transcription factor. This expression paradigm is 
exploited in Drosophila, using tissue-specific promoter to drive Gal4 expression (such as 
eye-specific GMR promoter) from one particular Gal4 line, which in turn direct tissue-
specific expression of desired gene cloned downstream of the UAS elements in another 
transgene. 
 
Figure 5. The UAS-GAL4 binary expression system 
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The strategy for this system is as the following: the gene of interest is placed under 
the UAS response element promoter site (normally in the vectors pUAST for expression in 
somatic tissues or pUASP for expression in germ lines) and inserted into the fly genome at 
random.  Expression of the GAL4 transcription factor is placed under the control of a 
Drosophila tissue specific response element. For example, GMR is an eye specific 
Drosophila response element recognized by a transcription factor that is primarily expressed 
in the eye, thus the GAL4 gene downstream of this response element will be expressed 
specifically in the eye.  In the presence of a UAS-transgene, it can then find the correct UAS 
site and express the gene downstream of the UAS site with tissue specificity.  In this way the 
expression of a transgenic gene can be accurately controlled.  Importantly, a vast number of 
tissue-, cell-type and-or temporal-specific Gal4 lines have been established in Drosophila.  
Which are easily available from several national and international Drosophila stock centers.  
Important to this study are the motor neuron specific D42-Gal4, pan-neuronal specific Elav- 
and Appl-Gal4, the latter is more specific for expression in adult stage on, and glial-specific 
Repo and GCM-Gal4 lines.  Thus, the employment of pUAST enables us to easily target 
hSOD1 transgene expression to any tissue of interest and examine their effects. 
Rationale 
Extensive studies have demonstrated that aggregates formation are tightly linked to 
pathogenesis of ALS and other neuronal degenerative diseases. In ALS, mutant SOD1 
proteins are known to be more prone to mis-folding and form protein aggregates. For 
example, in previous mammalian cell-based ALS models, in both neuron-like non-dividing 
NSC34 cells and dividing COS1 cells of monkey origin, GFP-tagged mutant human SOD1  
including mutations A4V, G85R and G93A, but not wild type hSOD1, developed aggregates 
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(Corcoran, Mitchison, & Liu, 2004; Matsumoto, Stojanovic, Holmberg, Kim, & Morimoto, 
2005). Thus, a detailed understanding of how cells respond to and regulate aggregates 
formation by mutant SOD1 will help elucidate the molecular mechanisms that control protein 
mis-folding and aggregation, and also potentially identify therapeutic targets for treating this 
deadly neurodegenerative disorder.  
Nevertheless, to our knowledge, except in Caenorhabditis elegans, few such 
systematic studies have been conducted in multicellular model organisms. In a reported C. 
elegans study, a genome-wide RNAi screen was carried out in a worm ALS model with pan-
neuronal expression of human G85R SOD1 mutant tagged with a yellow fluorescent fusion  
(YFP) reproter, from which more than 80 dsRNA hits that caused enhanced aggregates and 
diminished locomotion of the animal were isolated (Wang et al., 2009). We thus hypothesize 
that similar studies, in additional model organisms that include more strigent controls to 
screen for both suppressors and enhancers of mutant SOD1aggregates, will not only provide 
a more comprehensive picture of the aggregation regulators in the cell, but also help narrow 
down the conserved central players that control mutant SOD1 misfolding and accumulation. 
Previous studies have demonstrated that mutant human SOD1 can also form protein 
aggregates and induce animal toxicity in Drosophila, another well-established model 
organism (Wang et al., 2009; Watson et al., 2008). Accordingly , we have planned to use the 
tried and trusted versatile tools in this excellent animal model to systematic study the 
regulation of  aggregate formation by ALS associated human SOD1mutants. Our study is an 
important and logical next step, as most signlaing pathways are highly conserved between the 
fly and human, while a screen in the fly will be more cost effective and less time consuming 
than that in a mouse model. In addition, establishing, in parrallel, a whole-animal and also a 
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cell-based ALS model in Drosophila will allow for more extensive controls and easy 
validation of observations and results found in either model. With the previous experience in 
aggregates-centered screens on Huntington’s disease and resources that are readily available 
in our lab, we have expected that this ALS project will allow us to thoroughly and accurately 
evaluate the feasibility of employing Drosophila model to study the regulators of aggregates 
by mutant hSOD1, laying important foundation for more comprehensive studies in the future.  
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CHAPTER FOUR 
 
Molecular Cloning, Methods and Experimental Procedures 
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Molecular Cloning to Generate Fluorescent-tagged hSOD1 Fusion Protein 
 The four genetic variations of human SOD1 used in the project are A4V, G85R, and 
G93A and wild type (WT) control, as discussed in the previous chapter.  The cDNA clones 
containing each of the mutations and wild type hSOD1 were generously provided by Dr. 
Daryl Bosco (University of Massachusettes Medical School, Worcester).  The sequences of 
each SOD1 construct were verified by DNA sequencing after every cloning step.   
Each of the four genetic variations of hSOD1 will be fused in frame enhanced green 
fluorescent protein (eGFP) and to the red fluorescent protein; mCherry, a derivative of eGFP, 
thus a total of 8 fusion combinations. 
pMK33-hSOD1 constructs for cell line-based models  
 
The pMK33 vector is 8.5kbp in size and contains multiple restriction sites. For this 
project we utilized XhoI and SpeI, which correspondingly match an Xho1 C-terminal 
restriction site on PCR amplified hSOD1 cDNA and a SpeI site at the N-terminal of the PCR 
amplified eGFP and mCherry sequences (See details below in Summary of cloning 
procedures).  
pUAST-hSOD1 constructs for transgenic animals 
 
To generate transgenic fly models for SOD1, we used the transgenic vector pUAST, 
which is 9Kbp in size by itself.  It contains unique XhoI and XbaI cloning sites for the same 
aforementioned hSOD1 gene construct insertions (Also see details below in Summary of 
cloning procedures).  The vector also contains a mini-white gene, which restores the 
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Drosophila red eye phenotype in the otherwise white eye color w
1118
 flies, so as to allow 
easily determination of the success of transgenic events.  It also allows for the use of the 
UAS-GAL4 binary expression system to control tissue specific ectopic gene expression. 
Amplified and digested hSOD1 will be fused in frame at its N-terminus, through a PCR-
introduced Agel restriction site on the GS linker (see below), with the C-terminus of the 
chosen fluorescent marker.  
Thus, as there are 8 different combinations of hSOD1 varieties with eGFP and 
mCherry fusions.  In order to establish both the cell line- and the whole animal-based models 
to study regulators of aggregate formation by ALS-associated human SOD1 (hSOD1) 
mutants, we would need to clone them into the selected vectors.  A pUAST vector was 
utilized to establish the whole animal-based model, and the pMK33 vector utilized to 
establish the cell line-based model, thus for a total of 16 constructs, as summarized in Table 
1 of the results section.  
Summary of cloning procedures  
 
The cloning strategy involved seven steps. (1) Both wild type and mutant hSOD1 as 
well as the fluorescent reporters eGFP and mCherry were amplified by PCR, which used 
primers with added restriction enzyme sites such as XhoI or AgeI at both ends to facilitate 
cloning. A GS linker sequence encoding a short stretch of small amino acid glycine (G) and 
serine (S) was also added to one end of the primers, so as to fuse the SOD1 open reading 
frame with the eGFP or mCherry reporter; (2) The amplified SOD1 and eGFP/mCherry were 
cut with restriction enzymes and then purified with a gel extraction kit from Qiagen and 
stored at -20C until further use; (3) The cloning vector pUAST (for generating transgenic 
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flies) and pMK33 (cell transfection) were similarly cut with matching restriction enzymes 
and gel purified; (4) Next, a triple ligation of the digested vector, hSOD1 and eGFP or 
mCherry fragments was performed with T4 ligase ; (5) These ligations were transformed into 
competent E. coli bacteria cells and grown on selection plates for 16 hours, and correct 
clones were identified by PCR; (6) Extraction and purification of the plasmids was 
accomplished with Qiagen mini-prep kits; (7) Plasmid DNA were diagnosed with digestion 
by restriction enzymes and separation by agarose gel. The correct plasmids were further 
verified by Sanger DNA sequencing (Lone Star labs).   
List of primers: 
SOD1 forward primer:  5’-CTCGAGGAATTCCTAGAAATAATTTTGTTTAA-‘3 
SOD1 reverse primer with GS linker:   
5’-GTGTAATTGGGATCGCCCAAGGCGGATCCTCCGGAGGTACCGGT-3’ 
eGFP forward primer:  5’-GTGAGCAAGGGCGAGGAG-3’ 
eGFP reverse primer:  5’-CCCTGAACCTGAAACATAACTAGT-3’ 
mCherry forward primer:  5’-ATAACCGGTGTGAGCAAGGCGAGGAGG-3’ 
mCherry reverse primer:  5’- GGCTGATTATGATCTAGAGTCGCG-3’ 
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Summary of Protocols 
 
PCR protocol:  Either Taq or Phusion PCR polymerase was employed with the appropriate 
buffer. In general a master mix of PCR reagents was made and included in this order: 
deionize water, 10x or 5x buffer, dNTP at 200μM each, 0.5 μM of primers, 1μl of 
polymerase and 50 ng/μl of template DNA. A final volume of 25μl per PCR reaction, the 
reaction cycle included three stages, the first was denaturing at 98°C for 30 seconds and the 
second stage was 25-30 cycles which included a denaturation step at 98°C for 10 seconds, 
anneal step at 56°C for 23 seconds and extension step at 72°C for 1 minute and 20 seconds 
and then a final stage of extension at 72°C for 5 minutes. The final product was then purified 
using a Qiagen DNA purification Kit.  Although, some steps were not necessary and no 
modifications were made to the standard protocol.  
Restriction enzyme: All restriction enzymes used in the project required a buffer (NEB 
buffer number 4) containing 50mM Potassium Acetate, 20mM Tris-acetate, 10mM 
Magnesium Acetate, 1mM DTT and a pH of 7.9 at 25°C.  A master mix was used containing 
2 μl of New England Biolabs(NEB) buffer number 4, 0.3μl of each restriction enzyme, 1ng 
of template and 20μl deionized water per reaction. After digestion the entire reaction mixture 
was loaded into a 2% agarose gel with ethidium bromide to highlight DNA under ultra violet 
light and separated with 135mv for 12 minutes.  The gel was then visualized under UV light 
and the DNA bands of the correct size were excised from the gel and place into eppendorf 
tubes.  The DNA was then extracted from the agarose gel following the protocols from the  
Qiagen Gel Purification Kit which.   
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DNA Ligation protocol: T4 DNA ligase was used for all ligations with a buffer containing 
50mM Tris-HCl, 10mM MgCl2, 1mM ATP, 10mM DTT, at a pH of 7.5 at 25°C.  The 
components for a 20ul reaction were; 10x T4 DNA ligase buffer at 2μl, vector DNA 50ng 
and insert DNA 50ng, Nuclease-free water up to 20μl and 1μl of T4 DNA ligase. The 
ligation was then place in an 18°C incubator overnight but can also be performed at 25°C for 
one hour.  
E. Coli Transformation protocol: Transformation is a common molecular biology 
technique employed to select and amplify the newly generated DNA constructs after ligation 
of digested insert and vector DNA fragments.  This technique exploits the natural ability of 
some bacteria, specifically E.Coli used in this study, to accept and amplify foreign plasmids 
under certain treatment. In my study, I used a standard transformation protocol involved 7 
basic steps; (1) add ~11 μl of ligation sample to ~170μl of competent E. Coli. (2) Ice for 20 
mins to allow bacteria to settle and plasmids to settle on bacteria outer membrane surface.  
(3) Heat shock for no longer than 90 seconds at 42°C. This will open pores in the bacteria 
membrane and allow plasmids to enter. (4) Immediately ice for 20 minutes to allow bacteria 
to rest and the pores formed to close.  It is important not to disturb the bacteria during this 
time as they are in a very fragile state. (5) Add ~150μl of liquid broth and (6) incubate with 
constant agitation at 37°C for 40 to 50 minutes. (7)  Spread entire volume on an agar plate 
that contains antibiotic.  The plasmids used in this project contained an ampicillin resistance 
gene so that antibiotic was incorporated into the mixture when making the plate.  
Generating UAS-hSOD1-eGFP and UAS-hSOD1-mCherry transgenic flies 
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After sequence verification, the SOD1-eGFP or SOD1-mCherry constructs in pUAST 
vector were microinjected into w
1118
 fly embryos following standard protocol. The flies were 
allowed to mature and then crossed with w
1118
 virgins or males, and the resulting F1 
progenies was screened for restoration of red eye color from the white eye flies of the 
parental w
1118
 background, which indicated the success of transgenic events. The independent 
transgenic lines were then crossed to double balancer flies to map the chromosomal location 
of the transgenic inserts and also to balance the transgene in the genome.  Double balancer 
flies contain chromosomes that have been inverted and rearranged so that homologous 
recombination cannot occur.  This will help stabilize the inserted gene so it is not loss 
through generations of mating.  The balancer flies employed in this project were double 
balancer flies that contained second and third chromosome balancers.  They were 
distinguished by two phenotypes and two markers.  For the second chromosome the 
phenotype was a curly wing called cyo and a marker called sp that is recognized by a change 
in follicle grouping near the first leg on both sides.  The third chromosome phenotype was a 
change in bristle length on dorsal side of the thorax and it is called TM6C and a marker that is 
seen as a change in eye shape and is called dropper (Dr).   
Drosophila Genetics:  
 A total of 4 transgenic UAS-hSOD1-wild type fused to eGFP lines were tested during 
this project along with 3 lines for UAS-hSOD1 mutation A4V and G93A.  Two lines of 
transgenic UAS-hSOD1-G85R fused to eGFP and two lines fused to mCherry were also 
tested.  The transgene were mapped and their chromosomal locations were determined 
according to standard procedures using balancer stocks. For transgenic lines inserted on the 
second chromosome, they were subsequently balanced with SM5a, Cyo ; those on the third 
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chromosome were balanced with TM6c balancers.  The GAL4 lines selected to direct 
expression of the hSOD1 transgenic flies in this project were GMR-GAL4 (eye specific), 
D42 -GAL4 (motor neuron-specific) and GCM-GAL4 (glia cell during early development).  
Genotypes for GMR-GAL4 drivers: 
 The genotype of the progeny transgenic flies for UAS-hSOD1-WT-eGFP on the third 
chromosome after cross with GMR-Gal4 was: GMR-GAL4/+; UAS-hSOD1-WT-eGFP /+; 
+/+.  The genotype of the progeny transgenic flies for UAS-hSOD1-WT-eGFP on the second 
chromosome after cross with GMR was: GMR-GAL4/ UAS-hSOD1-WT-eGFP; + /+; +/+. 
The genotype of the transgenic, UAS-hSOD1-A4V-eGFP on the third chromosome, after 
cross with GMR-Gal4 was: GMR-GAL4/+; UAS-hSOD1-A4V-eGFP /+; +/+.  For the 
second chromosome it was GMR-GAL4/ UAS-hSOD1- A4V -eGFP; + /+; +/+. 
The genotype of the transgenic hSOD1-G85R-eGFP on the third chromosome, after cross 
with GMR-Gal4 was: GMR-GAL4/+; UAS- hSOD1-G85R-eGFP /+; +/+. For the second 
chromosome it was GMR-GAL4/ UAS-hSOD1- G85R -eGFP; + /+; +/+. 
The genotype of the transgenic UAS-hSOD1-G85R-wCherry on the third chromosome, after 
cross with GMR-Gal4 was: GMR-GAL4/+; UAS-hSOD1-G85R-mCherry /+; +/+. For the 
second chromosome it was GMR-GAL4/ UAS-hSOD1- G85R-mCherry; + /+; +/+. 
The genotype of the transgenic UAS-hSOD1-G93A-eGFP on the third chromosome, after 
cross with GMR-Gal4 was: GMR-GAL4/+; UAS-hSOD1-G93A-eGFP /+; +/+. For the 
second chromosome it was GMR-GAL4/ UAS-hSOD1- G93A -eGFP; + /+; +/+. 
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Genotypes for using motor neuron-specific D42-GAL4 drivers: 
The genotype of the progeny transgenic flies for UAS-hSOD1-WT-eGFP on the third 
chromosome after cross with motor neuron-specific D42-Gal4 line  was: D42-Gal4 /+; UAS-
hSOD1-WT-eGFP /+; +/+.  The genotype of the progeny transgenic flies for UAS-hSOD1-
WT-eGFP on the second chromosome after cross with D42-Gal4 line  was: D42-Gal4/ UAS-
hSOD1-WT-eGFP; + /+; +/+. 
The genotype of the transgenic, UAS-hSOD1-A4V-eGFP on the third chromosome, after 
cross with D42-Gal4 was: D42-Gal4/+; UAS-hSOD1-A4V-eGFP /+; +/+.  For the second 
chromosome it was D42-Gal4/ UAS-hSOD1- A4V -eGFP; + /+; +/+. 
The genotype of the transgenic hSOD1-G85R-eGFP on the third chromosome, after cross 
with D42-Gal4 line  was: D42-Gal4/+; UAS-hSOD1-G85R-eGFP /+; +/+. For the second 
chromosome it was D42-Gal4/ UAS-hSOD1- G85R -eGFP; + /+; +/+. 
The genotype of the transgenic UAS-hSOD1-G85R-wCherry on the third chromosome, after 
cross with motor neuron-specific D42-Gal4 was: D42-GAL4/+; UAS- hSOD1-G85R-
mCherry /+; +/+. For the second chromosome it was D42-GAL4/ UAS-hSOD1- G85R-
mCherry; + /+; +/+. 
The genotype of the transgenic UAS-hSOD1-G93A-eGFP on the third chromosome, after 
cross with motor neuron-specific D42-Gal4 was: D42-GAL4/+; UAS-hSOD1-G93A-eGFP 
/+; +/+. For the second chromosome it was D42-GAL4/ UAS-hSOD1- G93A -eGFP; + /+; 
+/+. 
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Genotypes for GCM-GAL4 drivers: 
The genotype of the progeny transgenic flies for UAS-hSOD1-WT-eGFP on the third 
chromosome after cross with GCM-GAL4 was: GCM-GAL4/+; UAS-hSOD1-WT-eGFP /+; 
+/+.  The genotype of the progeny transgenic flies for UAS-hSOD1-WT-eGFP on the second 
chromosome after cross with GCM was: GCM-GAL4/ UAS-hSOD1-WT-eGFP; + /+; +/+. 
The genotype of the transgenic UAS-hSOD1-G85R-eGFP on the third chromosome, after 
cross with GCM-GAL4 was: GCM-GAL4/+; UAS-hSOD1-G85R-eGFP /+; +/+. For the 
second chromosome it was GCM-GAL4/ UAS-hSOD1- G85R -eGFP; + /+; +/+. 
The genotype of the transgenic hSOD1-G85R-wCherry on the third chromosome, after cross 
with GCM-GAL4 was: GCM-GAL4/+; UAS-hSOD1-G85R-mCherry /+; +/+. For the second 
chromosome it was GCM-GAL4/ UAS-hSOD1- G85R-mCherry; + /+; +/+. 
 
Targeted overexpression of UAS-hSOD1-eGFP or UAS-hSOD1-mCherry using Gal4 
system 
 
The UAS-hSOD1-eGFP or UAS-hSOD1-mCherry transgenic flies were crossed to 
selected tissue-specific GAL4 drivers. Enabling us to check and verify correct transgene 
expression via western analysis, for phenotypic characterization and imaging documentation. 
For western analysis, 10 adult flies aged for 1 day expressing wild type hSOD1 and mutant 
G85R-hSOD1 fused to eGFP and mCherry, driven by the D42 (motor neuron) and GMR (eye 
specific) driver were homogenized in RIPO buffer.  The samples were separated with 
electrophoresis of a polyacrylamide gel and then transferred to a nitrocellulose membrane.  
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To detect proteins present on the membrane, anti-eGFP and mCherry antibodies were used. 
The membrane was then imaged with a LI-COR imager on western blot membranes.  
Dissection and staining of adult fly brain and ventral nerve cord 
 
Adult flies expressing A4V- or G93A-hSOD1 mutation with eGFP tag were dissected 
in 1X PBS to remove their brain and ventral nerve cord.  The samples were then fixed in 4% 
formaldehyde for 45 minutes, then stained with phlloidain and DAPI and placed on a slide to 
image with a fluorescent microscope.   
Imaging of adult fly eyes 
 
Flies expressing hSOD1 under the GMR-Gal4 eye specific driver were fixed to a 
slide with a fast drying clear liquid polymer and imaged with a fluorescent microscope. 
Images were taken under green or red UV illumination to visualize eGFP or mCherry signals 
and under bright light to image overall eye morphology.  
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CHAPTER FIVE 
 
Cloning Results and Assessing hSOD1 Aggregation Formation in 
Drosophila Cell Lines 
  
48 
 
 
Results of the Molecular Cloning  
  
Importantly, from the study, all the 16 constructs were successfully generated and sequencing 
verified (see Table 1).  The fly lines established thus far are displayed in Table 2. Thus, this 
work will establish the foundation for the ensuing cell- and whole animal-based studies. 
  
 
 
  
XhoI SpeI 
  
480bp 720bp 
  
 
 
 
 
  
XhoI XbaI 
(A
)
(B
)
Table 1. Experiment design and molecular cloning status 
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Table 2: Summary of established transgenic fly lines 
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To investigate establishing a cell-based model to study aggregate formation by 
mutant human SOD1 proteins, we first performed transient transfection assay to examine 
their expression from the established pMK33 constructs.  Further, we were able to test 
whether the mutant hSOD1 proteins form robust aggregates in the cell.  In the established 
pMK33 constructs, the expression of wild type and mutant hSOD1-eGFP or mCherry fusions 
were controlled under a copper-inducible metalothrenine protomor.  
The S2 cells selected for this project are a macrophage lineage Drosophila cell line 
that is commonly utilized for fruit fly related in vitro studies.  An advantaged of these cells is 
their relative robustness and hardiness when grown in S2 medium that has been supplimented 
with antibiotic and serum.  For this study the cells were specifically cultured in Schneider S2 
growth medium from invitrogen, which was supplamented with the antibiotics streptomycin 
and penicillian and with fetal bovine serum.   
The established pMK33 constructs were transfected into Drosophila S2 cells. 48 
hours after transfection, expression of fusion proteins were induced with aqueous copper 
sulfate solution at a final of concentration 250 mM. 
Pilot transfection assays 
 
In this study, S2 cells were first transfected with the pMK33 vector construct to 
assess proper expression of hSOD1 fused to eGFP under copper induction and they were 
assess visually for any obvious formation of mutant hSOD1-eGFP aggregates.  For this test 
transfection, all four pMK33 constructs containing eGFP-tagged wild type or each of the 
three selected hSOD1 mutants were used separately.  48 hours after SOD1 expression was 
induced with copper at a final concentration of 250mM, the cells were visualized under a 
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fluorescent micrscope.  Which revealed clear expression of each of the tested hSOD1-eGFP 
fusion, and the protein were predominantly localized to the cytosol, as expected. These 
observations suggested the successful transfection of the plasmids into the S2 cells and the 
proper induciton of SOD1 protein expression.  However, after 24, 48 and 72 hours of 
induction, we did not observe obvious aggregation by either wild type or any of the three of 
hSOD1 mutations.  
Co-transfection assays 
 
A second transfection strategy involved co-transfection of wild type hSOD1 fused to 
mCherry and mutant G85R-hSOD1 fused to eGFP.  The purpose of this stragey was to show 
a clear contrast between any presence of aggregated mutant G85R-hSOD1 (revealed by the 
green color of its eGFP tag) in the red background of a soulble wild type hSOD1 (revealed 
by its mCherry tag).  In addition, there exist reports suggesting that co-expression of wild 
type and mutant hSOD1 may promote more aggressive aggregation and disease phenotype 
(Deng et al., 2006; Graffmo et al., 2013; Jonsson et al., 2004). However, when examined 
under fluorsecent microscopy 18 hours (Figure 6) or 24 hours (data not shown) after  
induciton of protein expression, we again did not obseve obvious aggregate formation in 
either of the tested conditions.  
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In summary, results from the cell-based transfection assays suggest that human 
SOD1, either as wild type or each of the tested mutant forms, do not form robust aggregates 
in Drosophila S2 cells. Due to this observation, we did not further pursue establishing stably 
transfected cell lines, as originally planned. 
  
Figure 6. human SOD1 expression in Drosophila S2 cells. 
S2 cells were co-transfected with wild type hSOD1-mCherry  (red in A and D) and 
mutant G85R-hSOD1-eGFP (green in B and E). Images were taken 18 hours after 
induction of SOD1 expression, which were counter stained with DNA dye DAPI to 
reveal the cell nucleus (blue in C and F). Note that wild type and G85R mutant 
hSOD1 showed almost identical subcellular distribution pattern. Overlay of eGFP 
and DAPI channels (C and F) suggested that both wild type and mutant hSOD1 
mainly localize to the cytoplasm.  No obvious aggregation of SOD1 protein was 
observed. Imaged with 40X magnification with Zeiss Axio Fluorescent compound 
microscopy. 
  
A B C 
D E F 
Figure 6. hSOD1 expression in Drosophila S2 
cells 
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CHAPTER SIX 
Studying hSOD1Aggregation and Toxicity in Transgenic 
Drosophila Models 
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In this chapter of the study, we applied the UAS-Gal4 system to overexpress human 
SOD1 transgenes in different Drosophila tissues. We then analyzed the ability of WT and 
mutant hSOD1to form aggregates in vivo and their effects on animal behavior and survival. 
Confirmation of hSOD1 transgene expression in transgenic fly lines 
 
To first confirm the proper expression of the hSOD1-eGFP or hSOD1-mCherry 
fusion proteins from the established UAS-hSOD1 transgenic flies, we crossed the wild type 
and mutants A4V, G85R and G93A SOD1 lines with D42 (motor neuron) and GMR (eye) 
GAL4 drivers. These GAL4 driver lines provide tissue specific control over transgenic 
hSOD1 expression.  From each crosses, ten adult progenies containing both the GAL4 driver 
and UAS transgene were collected and homogenized to extract whole proteins, followed by 
western blot analysis to determine the success of protein expression from these transgenic 
lines.  
Figure 7 shows the results of the flies expressing wild type (WTSOD1-eGFP) and 
mutant G85R (G85R-h SOD1-eGFP) hSOD1 fused to eGFP (Figure 2A), as well as samples 
of the same mutant fused to mCherry (G85R-hSOD1- mCherry, Figure 2B).  Expression is 
controlled by either the motor neuron driver D42 GAL4 or the eye specific GMR driver. 
Expression of the fusion transgenes were detected with an anti-eGFP or anti-mCherry 
antibodies, respectively.  hSOD1 encodes a small 16 kDa protein, whereas eGFP and 
mCherry alone encodes 26kDa and 30kDa proteins, respectively.  Accordingly, the hSOD1-
eGFP and hSOD1-mCherry fusion proteins should be at around 42 kDa and 46kDa sizes, 
respectively.  Indeed, Western blot analysis confirmed the correct expression of these three 
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hSOD1 fusion proteins (WT-hSOD1-eGFP, G85R-hSOD1- eGFP and G85R-hSOD1- 
mCherry) at the predicted sizes, which were absent in the non-transgenic control flies (w
1118
 
and control lane in 7A and 7B).  
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Figure 7. Western blot analysis of ectopic human SOD1 expression in transgenic flies. 
 Human SOD1 is a 16kda protein. mCherry and eGFP encode proteins of about 30kda and 
26kda, respectively.  
(A) Samples from flies with wild-type hSOD1 or mutant G85R-hSOD1 expression under 
the eye specific GMR-Gal4 and motor neuron-specific D42-GAL4 driver, as 
highlighted by the green arrow.  Purified GFP alone was loaded in lane 2 as positive 
control (blue arrow). Sample from non-transgenic w
1118
 flies in lane 3 served as 
negative control. 
(B) Samples from flies with mutant G85R-hSOD1 expression (highlighted by the red 
arrow) under the eye specific GMR-Gal4 or motor neuron-specific D42-GAL4 driver. 
Purified mCherry alone was loaded in lane 2 as control (blue arrow). Sample from non-
transgenic w
1118
 flies in lane 3 served as negative control. 
Figure 7. Western blot confirmation of hSOD1 expression in transgenic flies 
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Quite interestingly, compared to WT-hSOD1-eGFP, the expression level of mutant 
G85R-hSOD1- eGFP was much lower in both D42 and GMR-Gal4 driven flies (Figure 2A). 
While the mutant G85R-hSOD1- eGFP protein also appeared to migrate slightly faster than 
the WT-hSOD1-eGFP in both cases, they have the same predicted protein size and differ 
only in one amino acid. Such a result, if held true, could suggest that the G85R mutation 
interferes with the stability of the expressed hSOD1 protein, rendering it unstable (i.e., 
reduced protein level) with potential conformational change (i.e., faster migration in the 
SDS-PAGE gel). Further studies are needed to verify the above observation, such as by using 
more independent UAS-hSOD1 transgenic lines for all three hSOD1 mutations and 
additional GAL4 drivers.  Another approach would be applying the recently developed attP 
targeted insert technique to direct both wild type and mutant hSOD1 to the same 
chromosome location in the fly genome, thus eliminating the potential positional effect on 
gene expression levels of different transgenic lines.  
Eye-specific over-expression of hSOD1 transgenes 
 
After confirming the correct expression of SOD1 fusion proteins from the transgenic 
lies, we first examine the effect of their overexpression in the fly eye by using the eye-
specific GMR-GAL4 driver. Drosophila’s eye is a popular tissue to characterize a gene’s 
function and is also ideal for analyzing the potential neuronal toxicity of a studied protein. 
Adult Drosophila has a compound eye, composed of about 800 single units called 
ommatidium.  Each ommatidium consists of neuronal bristles and eight photoreceptor cells, 
in addition to other non-neuronal accessory cells such as cone and pigment cells. In the 
normal adult eye, these ~800 eye units are patterned in a very regular and highly structured 
repetitive pattern, thus any mild effect on eye development will be magnified and easily 
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detected.  Moreover, because it is a sensitive neuronal tissue that is dispensable for animal 
viability, it is ideal to monitor the neurodegenerative consequences of a manipulated gene on 
this neuronal tissue over an extended period of time. For example, gradual damage to the eye 
cells has been often shown to present as an easily recognizable loss of red eye color, due to 
the loss of internal pigment cells.  Important to this study, as the eye is transparent, if the 
fluorescent-tagged mutant hSOD1 protein forms aggregates in the eye cells, they can be 
easily visualized directly under the fluorescent dissection microscope.  This can be 
performed without further dissection, as has been shown for aggregates-forming mutant 
Huntington protein (Zhang, Binari, Zhou, & Perrimon, 2010), thus greatly facilitating the 
monitoring for aggregates formation inside the eye.  
Figures 8-10 shows the adult Drosophila’s eyes at differt ages expressing 
fluorescent-tagged wild type and mutant hSOD1 from the transgenic flies, driven by the eye-
specific GMR-Gal4 driver.  
Figure 8 consists of images of eyes of 30-day-old adult flies expressing wild type 
hSOD1 and each of the mutant hSOD1 tagged with eGFP, along with eyes expressing mutant 
G85R-hSOD1 with mCherry tag.  When examined under bright field microscopy, all of these 
eyes have regular well-patterned morphology, suggesting that overexpression of wild type or 
either of the hSOD1 mutants does not affect normal eye development.  Notably, there is no 
clear loss of eye pigmentation in any of the hSOD1-expressing flies, even at age of day 70 
(Figure 9 for wild type and G85R-SOD1 mutation, the same was seen for A4V and G93A 
SOD1 mutants (data not shown).  Indicating that there is no significant cellular degeneration 
in these hSOD1-expressing flies, which further suggest that overexpressed hSOD1, either 
wild type or any of the mutant forms, are well-tolerated by Drosophila eye cells.   
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Figure 8. Ectopic expression of hSOD1-eGFP and hSOD1-mCherry in the adult eye under 
the eye-specific GMR-GAL4 driver.  
Age: 30 days as adults. Note that all the ommatidia appear well-organized and healthy, with no 
obvious  presence of aggregated hSOD1.   
 (A-E) are bright field images of the adult eyes that correspond to (F-J) of the same eyes under 
fluorescent illumination, respectively. 
 (A and F) wild type hSOD1-eGFP images.  
(B and G) hSOD1-A4V-eGFP.  
(C and H) hSOD1-G85R-eGFP.  
(D and I) hSOD1-G93A-eGFP.  
(E and J) hSOD1-G85R-mCherry.   
Figure 8. hSOD1 expression under eye-specific GMR-Gal4 driver 
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Figure 9. Ectopic expression of hSOD1-eGFP and hSOD1-mCherry in the adult 
eye under the eye-specific GMR-GAL4 driver.    
Age: 70 days as adults. Note that the ommatidia appear well-organized and healthy, 
and there was no clear presence of aggregated hSOD1 in all genotypes.   
(A-C) are bright field images of adult eyes that correspond to (D-F) the same eyes 
under fluorescent illumination. 
(A and D)  hSOD1-WT-eGFP. 
(B and E) hSOD1-G85R-eGFP.  
(C and F) hSOD1-G85R-mCherry.   
D 
B C 
F 
A 
E 
Figure 9. hSOD1 expression under eye-specific GMR-GAL4 
driver 
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When these hSOD1-expressing flies were visualized under fluoresecnt illumination to 
examine the expression of eGFP- or mCherry-tagged hSOD1, there was clear presence of the 
targeted proteins in the eyes. This observation is consistent with the confirmaiton by Western 
blot analyses, although their expression levels varied (Figures 3-5).  For example, the level of  
A4V-hSOD1 expression was much lower as compared to that of other hSOD1 lines (Figure 
3).  It is possible that such variation is potentially due to positional effect of different 
inserational sites, or it could suggest a reduced stablibility of the A4V mutant hSOD1 
protein.  Further studies are needed to clarify this potentially interesting issue.  
These exmainations also suggested that there were almost no visible aggregate 
formation in any of the hSOD1-expressing eyes (Figure 8-10), even in older flies at day 70 
(Figure 4).  Such an observation suggests that both wild type and either of the human SOD1 
mutants do not easily form aggregates in Drosophila eye cells, which is in sharp contrast to 
the prominent aggregates formation by mutant Hutintingtin protein expressed under similar 
condition (Zhang et al., 2010), 
To evaluate if co-expression of wild type hSOD1 could enhance the aggregation of 
mutant hSOD1 in Drosophila, as has been shown in mouse models (Deng et al., 2006), we 
simultaneously expressed wild type hSOD1-eGFP and  mutant G85R-hSOD1-mCherry in the 
eye (Figure 10). There was no observable enhancement of aggregation, although additional 
quantifition by Western blot remained needed to confirm this conclusion.  
  
61 
 
  
Day 23 
SOD1-G85R-mCherry + SOD1-WT-eGFP 
Day 30 
Figure 10. Co-expressing of wild type hSOD1 and mutant G85R-hSOD1 under 
eye-specific GMR-GAL4 driver.  
Age: day 23 (top panels) and day 30 (bottom panels) as adults, as indicated. 
From the left to right:  the same adult eyes illuminated under bright field light (left, to 
reveal overall eye morphology),  green fluorescent UV light (middle, to reveal wild 
type hSOD1-eGFP) and red fluorescent UV light (right, to reveal hSOD1-G85R-
mCherry ).  
Note that the eye morphology appeared normal and there was no prominent aggregates 
in both eyes, although there appeared to be stronger SOD1-eGFP signals in the 30-day-
old eye.  
Figure 10. Co-expression of WT & G85R hSOD1 in the Eye 
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 Motor neuron-specific expression of hSOD1  
  
Considering that ALS is a motor neuron degenerative disease, we further selected the 
motor neuron-specific GAL 4 driver D42 to target hSOD1 transgene expression. This D42 
driver will direct transgenic hSOD1 primarily in the motor neurons (Sanyal, 2009).  Several 
assays can be performed to investigate the effects of hSOD1 expression on animal behavior, 
viability as well as the subcellular distribution and potential aggregation of wild type and 
mutant hSOD1 proteins.  For example, the animals can then be monitored for locomotion 
defects such as the presentation or onset of paralysis.  These animals can also be dissected to 
obtain the adult brain and ventral nerve cord and examined under fluorescent compound 
microscopy to determine the cellular localization and potential presence and localization of 
aggregation of ectopically expressed hSOD1 proteins.  Stained with phlloidian to visualize 
the cytoskeleton and DAPI for the nuclei, the tissue can then be imagined with fluorescent 
microscopy.  The fluorescent tagged hSOD1 proteins in this expression system should label 
the motor neurons and show, in addition to the pattern of expression, the formation of 
aggregates in the motor neurons if they occur.  
The flies expressing hSOD1 directed by the D42 motor neuron GAL4 driver were 
aged for more than 90 days to assess their effects on animal locomotion and viability.  To do 
this, the D42>UAS-hSOD1 flies were transferred to new vials with fresh food every 3 days 
to prevent animal loss related to texture changes in the food, and the number of the survival 
flies were counted at that time.  Close observations of flies expressing mutation G85R under 
the D42 motor neuron driver showed no clear signs of paralysis or early decrease in mobility 
compared to hSOD1 wild type expression directed by the same driver.   These observations 
are supported by survivorship data collected on G85R mutant hSOD1 fused to eGFP and 
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mCherry with respect to wild type hSOD1 fused to eGFP both expressed in motor neurons of 
the flies. As presented in Figure 11 a total of 1,172 flies were counted, the mutant G85R-
hSOD1 expressing flies, driven by D42-GAL4, could live up to 104 days as adults, similar as 
that of the wild type w
1118
 control (data not shown). Further, the overall trends of survival 
curve between wild type SOD1 and mutant G85R-hSOD1expressing flies closely resembled 
each other (Figure 6). Similarly, gross observations of mutant A4V- and G93A-hSOD1 
expressing flies with D42 motor neuron revealed life span and mobility similar as that in 
WT-SOD1 flies (data not shown). Together, they suggest that animal mobility and life span 
are not significantly affected by mutant hSOD1 expression in Drosophila motor neurons. 
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Figure 11. Survival curve of adult flies expressing hSOD1 in motor 
neurons 
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We next carried out preliminary examination to check whether there existed protein 
aggregates formed by mutant SOD1 in these animals. Due to time restraints, we were only 
able to analyze flies expressing A4V-hSOD1 (Figures 12 and 13) and G93A-hSOD1 
mutants (data not shown).  From these flies, adult brain and ventral nerve cord were dissected 
and co-stained with phalloidin to visualize the actin cytoskeleton and DAPI dye for the 
nuclei. The image in Figure 7 is of a dissected adult fly brain and ventral nerve cord viewed 
at 10x magnification under fluorescent UV light to reveal of the expression of eGFP-tagged 
A4V-hSOD1. The image revealed areas of higher level expression of mutant A4V-hSOD1-
eGFP.  The brighter green areas in the image are actually the soluble A4V-hSOD1-eGFP 
expressed in motor neurons, (which, due to a high fluorescent background, might be 
confused as aggregation in a ubiquitous soluble A4V-hSOD1-eGFP expression context). 
When examined under fluorescent compound microscopy, there was clear presence of eGFP-
tagged A4V- and G93A-hSOD1 protein in motor neurons that was enriched in the cell body 
and also distributed along the whole axonal tract (Figure 7 and data not shown). However, 
there was no prominent aggregate formation by mutant A4V-SOD1 protein in these neurons, 
even in flies of 42 days of age (Figure 12).  
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Figure 12. Fluorescent image of an adult fly brain and ventral nerve cord expressing 
mutant A4V-hSOD1  fused to eGFP, driven by the motor neuron-specific D42-GAL4.  
In motor neurons, the expressed A4V-hSOD1-eGFP protein was enriched in cell bodies and 
also distributed evenly along the whole axonal tract. No prominent presence of aggregation 
of hSOD1 appears. Image was taken under10X magnification with Zeiss Axio Fluorescent 
compound microscopy. 
Figure 12. Adult brain and ventral nerve cord with motor neuron-specific 
expression of hSOD1 
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Upon closer examination, we found a few structures resembling hSOD1-derived 
aggregates scattered along axon tracts of motor neurons (Figure 13).  Some of these 
aggregates-like structures, enriched with eGFP-tagged mutant SOD1, also had accumulation 
of cytoskeleton protein F-Actin (Figure 8, top panels) while others did not (Figure 8, bottom 
panels). In the future, additional studies are needed to quantify these structures and determine 
whether such SOD1-enriched structures are indeed aggregates, for example by anti-ubiquitin 
antibody staining to see if they are modified by ubiquitination, a hallmark of aggregates from 
mis-folded proteins, or biochemical assay to examine their solubility in strong detergent such 
as SDS.  However, from our studies both in motor neurons (Figures 7 and 8) and in the eye 
(Figures 3-5), it is clear that neither forms of the examined hSOD1 mutants develop robust 
aggregates in fly cells.  
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Figure 13. Aggregation of mutant hSOD1-A4V-eGFP in motor neuron axons  
High magnification view of motor neuron axons with ectopic expression of hSOD1-
A4V-eGFP (green) driven by motor neuron-specific D42 driver, which were co-stained 
with phalloidin (red) to reveal actin cytoskeleton (F-actin).  
In top panels,  SOD1-A4v-eGFP aggregates (green) were also enriched with F-actin 
(red), as revealed in overlaying image (right) and highlighted by white arrows . 
Bottom panels are images of a motor neuron axon projecting from the ventral nerve 
cord.  A SOD1-A4v-eGFP aggregate (green) was present but was not enriched with F-
actin (red), as revealed in overlaying image (right) and highlighted by white arrow. 
Image was taken under 40X magnification with Zeiss Axio Fluorescent compound 
microscopy. 
  
Figure 13. hSOD1 expression under the D42 motor neuron GAL4 driver 
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Glia-specific over-expression of hSOD1 transgenes  
 
ALS has been described a non-cell autonomus disease and as such neuron 
degeneration depends not only on mutant protein expression in the neuron but also in the 
surronding astrocyte/glia cells. Considering this, we next tested the effect of wild type and 
mutant hSOD1 expression in Drosophila glia cells. To do this, we crossed the established 
UAS-hSOD1 transgenic lines with glia cell-specific Gal4 driver line gcm-Gal4 (specific 
promoter from the glia cell missing gene), which is expressed in almost all glial cells 
including cortex, as soon as they are born. Cortex glia cells in Drosophila are also referred to 
as cell-body-associated glia and are very similar to vertabrate astrocytes (Freeman & 
Doherty, 2006).  For this cross, a total of five line were selected for transgenic hSOD1 
directed expression with the GCM GAL 4 driver.  These line were two different G85R 
mutant lines fused to eGFP along with two lines of G85R fused to mCherry and one line of 
WT-hSOD1 fused to eGFP.  Our observation were that very few, if any, flies expressing 
hSOD1 in under the GCM GAL4 driver, either mutant G85R or wild type survived to adult 
hood.  Such a very interesting observation still needs furhter confirmation by using more 
independent hSOD1 lines, both for wild type and for different hSOD1 mutants. Also further 
testing should include additional glia-specific Gal4 driver such as repo-Gal4 as well as 
controls such as by pan-neuronal GAL4 driver elav-Gal4. 
However, it does raise an intriging possibility that high level of hSOD1 expresssion in 
glia cells is lethal to Drosophila. 
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Summary and Discussion 
 
We generated multiple UAS-hSOD1 transgenic lines and used available tissue-
specific Gal4 lines, to carry out preliminary analyses of the toxicity and aggregation property 
of the wild type and mutant human SOD1 proteins in different fly tissue and cell types. 
Although the study is still not completed yet and more controls and assasys are needed to 
validate our preliminary observations.  It is apparent at this point that human SOD1 protein, 
either as wild type or the three mutated forms we examined, does not form robust aggregates 
in different test settings. Included in our study is expression in cultured Drosophila S2 cells, 
in adult eyes over an extended peroid of time (up to 70 days) or in motor neurons.   
The original purpose of this project is to assess Drosophila as a model system to 
study aggregates by mutant hSOD1, and if successful, its long term goal is to identify 
regulators of aggregate formation by mutant hSOD1.  To faciliate these goals, our expression 
paradigm incorperates the fusion of a green or red fluorsecent protein to SOD1 proteins to 
allow easy visualization of SOD1 protein expression and their aggregation.  However, based 
on our preliminary results so far, hSOD1 does not easily form aggregates in either the S2 cell 
model or whole animal model in Drosophila. We will need to take serious re-consideration 
regarding the viability of pursueing hSOD1 mutants in this model system. 
Nevertheless, results so far also raised several interesting questions. For example, 
although both mutant Huntingtin and mutant SOD1 proteins form aggregates in human cells, 
they clearly behave very differently in term of aggrgates formation in Drosophila system. 
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Such a different behavior suggests that protein properties, and potentially aggregating 
dynamics, of mutant Huntingtin and mutant SOD1 are very different. Moreover, why even 
mutant forms of human SOD1 protein do not form robust aggregates even when expressed at 
a high level over an extended period of time?  One possibility is that protein quality control 
machineries in Drosophila cells, those involved in protein re-folding and in clearance of mis-
folded proteins, are more effective than their counterparts in mammalian systems in dealing 
with mutant SOD1 proteins. If this hypothesis is true, it raises a possibility that we can 
identify the machinery(ies) in Drosophila that can correct or clear the mis-floded mutant 
human SOD1 proteins, and harness its working mechanism to treat ALS. 
Another very intriguing observation is the lethality caused by the overexpression of 
either wild type or mutant G85R-hSOD1 specifically in glia. Notably, overexpression of 
these proteins in the eye or motor neurons do not lead any obvious detrimental effect. 
Although furhter studies are required to confirm the above observations, they raise a very 
intersting possibility that glia cells are especially vulnearble to SOD1 expresion. Moreover, 
existing findings from mammalian studies already support that nonautonomous effect from 
astrocyte and glia contribute significantly to the ALS pathogenesis. Together, they present a 
question whether the lethality associaited with glia-specific expresssion of SOD1 share some 
mechanistic similarity with the pathogensis underlying ALS. 
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CHAPTER SEVEN 
Perspectives 
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Toxicity and aggregation of human SOD1 protein in Drosophila 
 
The results obtained during the study of this thesis project were consistent with a 
previously established ALS models using hSOD1 in Drosophila (Watson et al., 2008). In that 
study wild type hSOD1 and hSOD1 with A4V and G85R mutations were examined for 
neuronal toxicity in Drosophila.  Expression of human SOD1 in Drosophila was directed by 
the GMR (eye specific) and D42 (motor neuron) Gal 4 drivers.  The flies were examined for 
deficits in motor function and life span, as well subject to Western analysis, motor neurons 
counts and electrophysiology.   It was found that  although progressive climbing difficulty 
was recorded with both wild type and mutant hSOD1 expression in motor neurons,  there was 
no significant loss of motor neurons nor obvious signs of paralysis (Watson et al., 2008).  
Toxicity of wild type hSOD1 was confirmed with electrophysiology studies and showed 
similar defect to that seen in G85R flies.  The results suggest the giant fiber circuit is 
defective when given high frequency stimulation, revealing defects in synaptic transmission 
of older flies expressing wild type and G85R mutant hSOD1 in motor neurons (Watson et al., 
2008).  Further, their life span data for motor neuron directed expression of WT and mutant 
hSOD1 flies revealed similar survivorship curves as their control flies which expressed GFP 
only under the same D42 driver (Watson et al., 2008).  Finally, they found that focal 
accumulation of hSOD1 protein did occur when directed by the eye-specific GMR-Gal4 and 
motor neuron-specific D42 drivers, and that in motor neurons it was accompanied by a stress 
response in surrounding glia cells (Watson et al., 2008).  Interestingly, the study did observe 
the same change to migration rate of mutation G85R of hSOD1 in western analysis (Watson 
et al., 2008). Interestingly, the study did observe the same change to migration rate of G85R-
hSOD1 mutation in Western analysis (Watson et al., 2008). Notably, they concluded that 
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neuronal toxicity was not the result of hSOD1 aggregates and hSOD1 expression did not 
cause a loss of neurons (Watson et al., 2008).   Our current study, with respect to a lack of 
obvious paralysis and unaffected life span in mutant hSOD1-expressing flies as compared 
with ones with wild type hSOD1 expression, is consistent with this previous work. 
The previously established model by Watson et al, however, did not employ hSOD1 
fused to eGFP or mCherry fluorescent reporters, in contrast to our model.  Thus, this suggests 
that the fusion of a fluorescent protein to wild type and mutant hSOD1 does not increase or 
decrease its toxicity in Drosophila.  In addition, fusing fluorescent proteins to hSOD1 does 
not appear to adversely affect the solubility and subcellular localization of hSOD1 in 
Drosophila.  Although the Waston et al 2008 study reported the toxicity of SOD1 protein in 
the fly, as manifested as a decrease in geotaxis response (Watson et al., 2008), we have yet to 
confirm this observation using our SOD1 model.  However, we did observe the presence of 
aggregates-like structures in neurons of SOD1-expressing animals when examined under 
fluorescent microscopy (Figure 7). Further studies are needed to clarify this observation. 
Glia-specific toxicity of human SOD1 protein in Drosophila? 
 
Interestingly, in our current study, when wild type or mutant hSOD1 transgenic flies 
were crossed with a glia cell specific GAL4 driver, gcm-GAL4, a surprising lethality 
phenotype emerged that suggests expression of hSOD1 in this tissue could be lethal.  ALS 
caused by SOD1 mutations in general has been described as a non-cell autonomous disease 
(Boillee, Vande Velde, et al., 2006; Boillee, Yamanaka, et al., 2006; Da Cruz & Cleveland, 
2011; Nagai et al., 2007; Tamura, Sone, Yamashita, Wanker, & Okazawa, 2009; Wallis et 
al., 2012).  Non-cell autonomy is a term here to describe the nature of toxicity as dependent 
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on the involvement of surrounding cell or tissues.  Glia and astrocyte cells are known as 
support cells for neurons but recently their true nature of involvement with functions of 
neurons and synaptic transmission has been revealed to be very complex (Volterra & 
Meldolesi, 2005).  It is now known that astrocytes are indeed excitable and express in their 
membrane many of the same receptors and channels expressed by neurons (Volterra & 
Meldolesi, 2005).  Perhaps most notably astrocytes play a major role in sequestering 
glutamate from the synaptic cleft, to avoid it remaining in the cleft and causing 
excytotoxicity of neurons. The loss of the astrocyte glutamate reuptake transporter EAAT2 
has been seen in ALS and is believed to be a major contributor of glutamate related 
excytotoxicity (Howland et al., 2002; Wallis et al., 2012).  In addition astrocytes release 
trophic factors to neurons such as TNFα, which induces insertion of AMPA receptors into the 
plasma membrane (Yin et al., 2012). AMPA receptors are the key metabotropic excitatory 
receptors for which the agonist is glutamate.  However, in advanced stages of the disease 
progression the increased in TNFα release by astrocytes becomes toxic to neurons (Yin et al., 
2012). 
Future studies based on the established SOD1 models in Drosophila 
 
More work can be carried out to further test the above hypotheses using our hSOD1 
models. First, in the whole animal models, it should include ubiquitous expression of both 
wild type and mutant hSOD1, to more comprehensively determine the presence of an 
aggregation phenotype.  In doing so, we can also determine whether the hSOD1-induced 
lethality phenotype observed under the glia cell gcm-GAL4 driver is truly glia-specific. 
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Second, of the current SOD1 model in S2 cells, which does not form robust 
aggregates, it is possible that Drosophila S2 cells are expressing a gene alone or of a pathway 
that is capable of completely suppressing aggregate formation by mutant hSOD1. In such a 
scenario, our S2 cell-based SOD1 models could be used to conduct the proposed genome-
wide RNAi screen to reveal such a protective gene or pathway(s), potentially leading to a 
new and exciting research direction.   
Further, Drosophila S2 cells are macrophage lineage cells, which are immune system 
cells, not neuronal cells.  Since ALS is a neurodegenerative disease, switching to a 
Drosophila neuronal cell line may yield different results with regard to aggregate formation.  
With regard to copper homeostasis, Drosophila S2 cells contain copper chaperones that are 
powerful regulators of free copper (Southon, Burke, Norgate, Batterham, & Camakaris, 
2004).  hSOD1 has been shown to accumulate and aggregate in neurons, astrocytes and 
mitochondria (Cozzolino et al., 2009; Jaiswal et al., 2009; Nguyen et al., 2009).  Aggregation 
of any protein in a cell is a concentration dependent process, which means it inherently 
requires accumulation of significant amount of mis-folded proteins and thus the expression 
level of the protein will be an important factor in aggregation process. On this aspect, our S2 
cell-based model employs copper induction of hSOD1 expression, while an enzymatically 
active hSOD1 by itself is required to complex with copper and zinc, thus titration of aqueous 
copper may be necessary to optimize its hSOD1expression.  Another possibility would be to 
codon optimize the inserted hSOD1 gene, to the codons preferred by the Drosophila species.  
This has been suggested by the advising committee over this project and is postulated to 
result in a noticeable difference in phenotype presentation.  
 
76 
 
Cellular toxicity in ALS:  a link between dysregulated neuronal excitability, aggregates 
and others? 
 
The underlying cellular and molecular mechanisms underlying ALS are still far from 
clear. Nevertheless, it is quite intriguing to observe a link between dysregulated neuronal 
excitability, aggregates formation and other cellular factors in ALS pathogenesis. 
To facilitate normal neuronal communication neurons must generate action potentials 
to allow an influx of calcium, which then signals the release of neurotransmitter to the 
synaptic cleft.  Action potentials are propagated by and result from the opening of voltage 
gated sodium channels, which allow for an influx of positively charged sodium ions, thereby 
depolarizing the neuron.  This sodium current allows for a spike in voltage, which is 
propagated down the axon to the synaptic cleft.  That action causes the necessary increase in 
calcium concentration, which then facilitates the binding of vesicles to the inner membrane 
of the neuron, subsequently the vesicle fuses with the membrane and opens to the synaptic 
cleft to release its neurotransmitter contents.  The neurotransmitter molecules travels across 
the synaptic cleft from the presynaptic neuron to the post synaptic neuron and eventually 
cause either an inhibitory postsynaptic potential or and excitatory post synaptic potential 
(IPSP or an EPSP).  
 All neurons maintain a negatively polarized resting membrane potential that is 
caused by negatively charged proteins and DNA. The resting membrane potential is 
maintained at around -65mV by high intracellular potassium concentration.  However, for an 
action potential to occur the membrane must depolarize to a certain threshold potential and 
then an all or nothing response in the form of an action potential is generated.  An increase in 
intracellular chloride, mediated by GABA channels, can prevent current from cation channels 
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depolarizing the membrane. This action will then inhibit the neuron from reaching the 
depolarized threshold necessary to generate an action potential.  Increases in depolarizing 
threshold have been seen in ALS motor neuron axons and it has been suggested to be 
attributed to dysfunction in either expression of or conductance of potassium channels. 
(Cheah et al., 2012; Shibuya et al., 2011)  However, an accumulation of negatively charged 
proteins could be the underlying cause of that dysfunction and subsequent increase in 
excitability.  hSOD1 has a net negative charge of -6 and mutated SOD1 maintains the same 
charge or in some cases decreases, but only slightly, while in other cases such as G127X the 
net negative charge increases. (Sandelin, Nordlund, Andersen, Marklund, & Oliveberg, 2007) 
Mutated proteins, such as SOD1, at some point lose functionality and accumulate while 
remaining soluble and then aggregate.  In this quasi-stable state of soluble accumulation the 
negatively charged proteins may be able to aberrantly contribute to the global negative 
charge of a cell.  This may result in changes to cation conductance and produce excessive 
inhibition of action potentials.  Thus, the neuron in cooperation with astrocytes struggles to 
overcome excessive inhibition and in the process becomes over excitable.   
In support of the above hypothesis, in addition to the dysfunction seen of potassium 
channel in ALS models, the following findings are noteworthy.  First, it has been shown that 
some mutant forms of SOD1 develop less soluble yet toxic aggregates, then become more 
toxic when soluble yet mis-folded, but then becomes less toxic when correctly folded by 
chaperones.(Brotherton, Li, & Glass, 2012). The less soluble but more aggregated SOD1 
mutants become very toxic when solubilized until correctly folded by chaperones (Brotherton 
et al., 2012). This evidence supports that mutant SOD1 is most toxic when mis-folded and 
accumulated while still in electrochemical contact within the cell.  Second, an increase in 
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persistent inward sodium conductance has been seen in ALS and causes increased 
excitability. (Kiernan, 2009; Meehan et al., 2010; Shibuya et al., 2011)  Third, TNFα release 
by astrocytes is increased which actually induces AMPA receptor insertion into the 
membrane, while later with disease progression it becomes toxic.  (Boillee, Vande Velde, et 
al., 2006; Yin et al., 2012)  Overexpression of AMPA receptors will markedly increase 
excitability and has been well established to play a prominent role in ALS.  Fourth, 
astrocytes have been shown to release d-serine which is a stronger agonist for NMDA 
receptors than glycine and can actually increase their ability to conduct cations. (Sasabe et 
al., 2007)  NMDA up regulation in this manner has been seen in ALS and leads to an 
increase in excitability, which in turn leads to an increased cytoplasmic calcium 
concentration (Sasabe et al., 2007; Spalloni, Nutini, & Longone, 2013)  Fifth, the loss of 
EAAT2 glutamate transporter in astrocytes results in an increase in the concentration of the 
main excitatory neurotransmitter glutamate in the synaptic cleft, which in turn will cause 
excessive activation of NMDA and AMPA receptors (Howland et al., 2002).  Consequently, 
again leading to increased calcium concentration in the neuron, a sign of excytotoxicity, and 
a result of increased excitability.   
ALS and athleticism: a causative or an incidental link? 
 
Some studies have shown a correlation between prolonged strenuous activity, such as 
athletics or occupations that require intense physical activity and onset of ALS (Scarmeas, 
Shih, Stern, Ottman, & Rowland, 2002; Sutedja et al., 2009). One most famous case of ALS 
is Lou Gehrig, an outstanding baseball player who fell victim to the ALS during the peak of 
his career, and ALS has often or better known by general public, as Lou Gehrig’s disease.  
Notably, in ALS, the changes to neurons with regard to sodium and potassium channel 
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conductance are seen well before symptoms start and are suggested to appear early in life.  If 
there is a higher degree of excitability in motor neurons that occurs well before onset of 
symptoms, it could translate to an increase in stamina. High stamina can lead to success 
when engaged in physically demanding activities such as athletics.  Just as a general increase 
in energy level that may be the underlying reason for a lower body mass index (O'Reilly et 
al., 2013). There is a remote possibility that it may not be exercise or environmental factors 
that contribute to ALS; it may be that the underlying cellular mechanisms of ALS make 
patients more likely to be active at a younger age.   
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